Mid-cap biotechs join Trump’s latest round of drug pricing deals

By:
On:
URL has been copied successfully!

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies.

Please follow us:
Follow by Email
X (Twitter)
Whatsapp
LinkedIn
Copy link

This post was originally published here.